Thiazole analog as stearoyl-CoA desaturase 1 inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5214-5217

  Li, Chun Sing ^a   Belair, Liette ^a   Guay, Jocelyne ^a   Murgasva, Renata ^a   Sturkenboom, Wayne ^a   Ramtohul, Yeeman K ^a   Zhang, Lei ^a   Huang, Zheng ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

MF 152; Obesity; SCD1; Stearoyl CoA desaturase 1 inhibitor; Thiazole; Type 2 diabetes

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE INHIBITOR; MF 152; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALOPECIA; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; IC 50; LIPID STORAGE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RAT; SCID MOUSE; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PIPERAZINES; RATS; STEAROYL-COA DESATURASE; THIAZOLES;

ANIMALIA;

EID: 68349157394     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.015     Document Type: Article

References (23)

1. Enoch H.G., Catala A., and Strittmatter P. J. Biol. Chem. 251 (1976) 5095
2. Ntambi J.M. Prog. Lipid Res. 34 (1995) 139
3. Miyazaki M., Kim Y.-C., Gray-Keller M.P., and Attie A.D. J. Biol. Chem. 275 (2000) 30132
4. Ntambi J.M., Miyazaki M., Stoehr J.P., Lan H., Kendziorski C.M., Yandell B.S., Song Y., Cohn P., Friedman J.M., and Attie A.D. Proc. Natl. Acad. Sci. U.S.A 99 (2002) 11482
5. Jiang G., Li Z., Liu F., Ellsworth K., Dallas-Yang Q., Wu M., Ronan J., Esau C., Murphy C., Szalkowski D., Bergeron R., Doebber T., and Zhang B.B. J. Clin. Invest. 115 (2005) 1030
6. Gutierrez-Juarez R., Pocai A., Mulas C., Ono H., Bhanot S., Monia B.P., and Rossetti L. J. Clin. Invest. 116 (2006) 1686
7. Liu G., Lynch J.K., Freeman J., Liu B., Xin Z., Zhao H., Serby M.D., Kym P.R., Suhar T.S., Smith H.T., Cao N., Yang R., Janis R.S., Krauser J.A., Cepa S.P., Beno D.W., Sham H.L., Collins C.A., Surowy T.K., and Camp H.S. J. Med. Chem. 50 (2007) 3086
8. Liu, G.; Zhao, H.; Serby, M. D.; Smith, H. T.; Cao, N.; Surowy, T. K.; Adler, A.; Mika, A.; Farb, T. B.; Keegan, C.; Landschulz, K.; Brune, M.; Collins, C. A.; Sham, H. L.; Camp, H. S. The 233rd ACS National Meeting, Chicago, IL, March 25-29, 2007; Abstract: MEDI 232.
9. Winther, M. D. 2nd Annual Drug Development for Diabetes and Obesity, London, UK, 2008, Jan 17-18.
10. Attie A.D., Krauss R.M., Gray-Keller M.P., Brownlie A., Miyazaki M., Kastelein J.J., Lusis A.J., Stalenhoef A.F., Stoehr J.P., Hayden M.R., and Ntambi J.M. J. Lipid Res. 43 (2002) 1899
11. Hulver M.W., Berggren J.R., Carper M.J., Miyazaki M., Ntambi J.M., Hoffman E.P., Thyfault J.P., Stevens R., Dohm G.L., Houmard J.A., and Muoio D.M. Cell Metab. 2 (2005) 251
12. Nakamura M.T., and Nara T.Y. Annu. Rev. Nutr. 24 (2004) 345
13. The study of a small molecule of SCD inhibitor was reported recently, Ref. 6b.
14. Five applications from Xenon (WO2005/011653 to WO 2005/011657) were published on February 10, 2005. Representative one: Abreo, M.; Chafeev, M.; Chakka, N.; Chowdhury, S.; Fu, J.-M.; Gschwend, H. W.; Holladay, M. W.; Hou, D.; Kamboj, R.; Kodumuru, V.; Li, W.; Liu, S.; Raina, V.; Sun, S.; Sun, S.; Sviridov, S.; Winther, M. D.; Zhang, Z. WO2005/011655.
15. Zhao H., Serby M.D., Smith H.T., Cao N., Suhar T.S., Surowy T.K., Camp H.S., Collins C.A., Sham H.L., and Liu G. Bioorg. Med. Chem. Lett. 17 (2007) 3388
16. Xin Z., Zhao H., Serby M.D., Liu B., Szczepankiewicz B.G., Nelson L.T.J., Smith H.T., Suhar T.S., Janis R.S., Cao N., Camp H.S., Collins C.A., Sham H.L., Surowy T.K., and Liu G. Bioorg. Med. Chem. Lett. 18 (2008) 4298
17. A structurally distinct class of SCD inhibitor was published during the preparation of this Letter. Koltun D.O., Parkhill E.Q., Vasilevich N.I., Glushkov A.I., Zilbershshtein T.M., Ivanov A.V., Cole A.G., Henderson I., Zautke N.A., Brunn S.A., Mollova N., Leung K., Chisholm J.W., and Zablocki J. Bioorg. Med. Chem. Lett. 19 (2009) 2052
18. There was a patent application on five-membered heterocycles during the course of this work. However, examples disclosed are very limited in scope. Kamboj, R.; Zhang, Z.; Fu, J.-M.; Kodumuru, V.; Liu, S.; Sun, S.; Chakka, N. WO2006/034315.
19. Rat microsomal assay conditions: Li, C, S.; Ramtohul, Y.; Huang, Z.; Zhang, L.; Lachance, N. WO2006/130986.
20. Zhang, L.; Ramtohul, Y.; Gagné, S.; Styhler, A.; Wang, H.; Guay, J.; Huang, Z. J. Biomol. Screen, accepted for publication.
21. 2 atmosphere. However, compound 1 has a total of 10 metabolites with the hydroxylation metabolite 2 as major product whereas compound 13 has only three metabolites with the acid 16 as the major metabolite. Some of these metabolites from both compounds were confirmed with synthetic standard and not all metabolites were fully characterized.
22. Food consumption was not vigorously measured for this exploratory experiment. There were ∼5% less food consumptions for both compound 13 and AM251, but they were not statistically significant in this study. Subsequent studies showed that compound 13 does not appear to have effect on food consumption (unpublished results).
23. Lan R., Liu Q., Fan P., Lin S., Fernando S.R., McCallion D., Pertwee R., and Makriyannis A. J. Med. Chem. 42 (1999) 769